Marshall Wace’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $85.6M | Buy |
+381,296
| New | +$95M | 0.09% | 204 |
|
|
2025
Q4 | – | Sell |
-310,987
| Closed | -$85.1M | – | 3405 |
|
|
2025
Q3 | $85.1M | Buy |
310,987
+298,412
| +2,373% | +$81.5M | 0.09% | 202 |
|
|
2025
Q2 | $3.24M | Sell |
12,575
-543,857
| -98% | -$130M | ﹤0.01% | 1336 |
|
|
2025
Q1 | $125M | Buy |
556,432
+548,581
| +6,987% | +$128M | 0.16% | 109 |
|
|
2024
Q4 | $1.8M | Sell |
7,851
-395,621
| -98% | -$95.3M | ﹤0.01% | 1491 |
|
|
2024
Q3 | $98.5M | Sell |
403,472
-275
| -0.1% | -$61.4K | 0.12% | 148 |
|
|
2024
Q2 | $77.3M | Buy |
+403,747
| New | +$81.9M | 0.1% | 186 |
|
|
2024
Q1 | – | Sell |
-60,191
| Closed | -$10.4M | – | 2753 |
|
|
2023
Q4 | $10.4M | Sell |
60,191
-626,702
| -91% | -$96.3M | 0.02% | 682 |
|
|
2023
Q3 | $102M | Buy |
686,893
+339,755
| +98% | +$61.4M | 0.21% | 96 |
|
|
2023
Q2 | $75.8M | Sell |
347,138
-101,763
| -23% | -$22.7M | 0.15% | 146 |
|
|
2023
Q1 | $98.3M | Buy |
448,901
+304,717
| +211% | +$66.1M | 0.21% | 106 |
|
|
2022
Q4 | $30M | Buy |
144,184
+39,768
| +38% | +$8.74M | 0.07% | 328 |
|
|
2022
Q3 | $22.8M | Buy |
104,416
+44,497
| +74% | +$10.1M | 0.05% | 414 |
|
|
2022
Q2 | $12.6M | Buy |
+59,919
| New | +$12.8M | 0.03% | 714 |
|
|
2022
Q1 | – | Sell |
-220,415
| Closed | -$57.4M | – | 3918 |
|
|
2021
Q4 | $57.4M | Buy |
220,415
+108,467
| +97% | +$28.1M | 0.11% | 185 |
|
|
2021
Q3 | $29.5M | Buy |
111,948
+37,997
| +51% | +$10.4M | 0.12% | 171 |
|
|
2021
Q2 | $18.2M | Sell |
73,951
-42,393
| -36% | -$8.91M | 0.08% | 257 |
|
|
2021
Q1 | $22.6M | Buy |
116,344
+35,882
| +45% | +$7.2M | 0.1% | 198 |
|
|
2020
Q4 | $17.1M | Buy |
80,462
+3,088
| +4% | +$616K | 0.09% | 215 |
|
|
2020
Q3 | $13.3M | Buy |
+77,374
| New | +$14.3M | 0.08% | 237 |
|
|
2020
Q2 | – | Sell |
-20,496
| Closed | -$3.02M | – | 1881 |
|
|
2020
Q1 | $3.02M | Buy |
20,496
+1,441
| +8% | +$230K | 0.03% | 501 |
|
|
2019
Q4 | $2.95M | Buy |
+19,055
| New | +$2.75M | 0.02% | 696 |
|
|
2018
Q4 | – | Sell |
-357,549
| Closed | -$41.2M | – | 1775 |
|
|
2018
Q3 | $41.2M | Buy |
357,549
+293,582
| +459% | +$32.2M | 0.35% | 67 |
|
|
2018
Q2 | $6.63M | Buy |
+63,967
| New | +$6.47M | 0.1% | 243 |
|
|
2017
Q4 | – | Sell |
-10,595
| Closed | -$816K | – | 469 |
|
|
2017
Q3 | $816K | Buy |
+10,595
| New | +$810K | 0.04% | 244 |
|
|
2017
Q1 | – | Sell |
-54,322
| Closed | -$3.37M | – | 673 |
|
|
2016
Q4 | $3.37M | Buy |
+54,322
| New | +$3.33M | 0.02% | 552 |
|
|
2016
Q3 | – | Sell |
-79,356
| Closed | -$5.02M | – | 1108 |
|
|
2016
Q2 | $5.02M | Sell |
79,356
-35,136
| -31% | -$2.07M | 0.04% | 386 |
|
|
2016
Q1 | $6.62M | Buy |
114,492
+93,389
| +443% | +$5.29M | 0.06% | 283 |
|
|
2015
Q4 | $1.13M | Buy |
+21,103
| New | +$1.19M | 0.01% | 682 |
|
|
2014
Q4 | – | Sell |
-23,001
| Closed | -$1.13M | – | 938 |
|
|
2014
Q3 | $1.13M | Buy |
23,001
+5,274
| +30% | +$269K | 0.02% | 533 |
|
|
2014
Q2 | $898K | Sell |
17,727
-60,718
| -77% | -$3.01M | 0.01% | 519 |
|
|
2014
Q1 | $3.51M | Buy |
+78,445
| New | +$3.52M | 0.06% | 275 |
|
Other funds holding RMD
VCM
VPM
DAM
Marshall Wace's RMD Position: Q1 2026 in Review
Marshall Wace opened a new position in ResMed (RMD) in Q1 2026: 381,296 shares worth $85.6M. The stake represents 0.09% of the portfolio and ranks #204 among its holdings. This is a return to the name: Marshall Wace previously reported a position in RMD as recently as Q3 2025.
Marshall Wace first reported a position in RMD in Q1 2014 and has held it in 32 quarters since. The position peaked at $125M in Q1 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.
- Marshall Wace held 381,296 shares of ResMed worth $85.6M as of Q1 2026.
- ResMed was a new Marshall Wace position in Q1 2026.
- ResMed made up 0.09% of Marshall Wace's portfolio in Q1 2026, its #204 holding.
- Marshall Wace first reported a position in ResMed in Q1 2014 and has held it in 32 quarters since.
- Marshall Wace's ResMed position peaked at $125M in Q1 2025.
- 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.